Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

Dispersion was extreme. MRNA led at +47.50% ($130.38 → $192.31), finishing at $182.11 and closing 83.35% of its range, while KPTI anchored the bottom at -39.95% ($2.07 → $1.24) — a ~87-point spread between the two tails. TEM (+41.77%), EBS (+28.18%) and HIMS (+19.00%) filled out the upside; CDXS (-25.07%), SYK (-19.46%) and STIM (-19.08%) the downside.

Implied volatility misfired in both directions. TEM was the biggest surprise at 4.98x realized-vs-implied, with SYK (3.33x), MRNA (3.25x), EBS (3.19x) and THC (2.58x) also moving far more than options priced. The reverse held in the highest-IV names: DBVT (230.08% IV, 0.36x), CDXS (213.28% IV, 0.54x), MGNX (0.67x) and QURE (0.76x) all delivered less than their premiums implied.

Closing location split cleanly along direction. ADMA closed nearest its high at 88.85%, with MRNA and ABBV (81.17%) firm. CVS closed nearest its low at 1.25%, joined by BMY (1.33%), CI (5.35%), MGNX (4.23%) and UNH (13.06%) — decliners finishing on their lows rather than bouncing.

Broader Market Context

Differential behavior within the sector. This is not a sector moving as a block. Large-cap pharma and devices clustered in a narrow band — ABBV +9.17%, MRK +7.90%, GILD +7.88%, LLY +6.79% against JNJ -7.25%, BMY -10.50%, ABT -11.92%, AMGN -16.01% — with the sector ETF proxy XLV down just 5.37% and carrying the lowest realized volatility in the report (14.50%). Underneath that calm index-level tape, biotech and small-cap names swung 40-50 points in either direction. Managed care was uniformly heavy: UNH -9.97%, HUM -12.11%, CVS -13.03%, CI -8.22%, all closing in the bottom quartile of their ranges, while CNC gave back an early spike to close at 3.07%. That within-sector spread dwarfs the sector's own move versus the market.

Rotation versus idiosyncratic risk. The pattern looks more stock-specific than rotational. True sector rotation typically produces correlated moves; here gainers and decliners coexist with similar market caps and business lines. The clustering of payors and providers (UNH, HUM, CVS, CI, ELV fading from its high) is consistent with a shared cost- or reimbursement-driven theme, while the biotech extremes (MRNA, TEM, KPTI, CDXS, QURE) look driven by name-level catalysts. XLV's muted realized volatility suggests capital churned *within* healthcare rather than wholesale in or out of it.

Plausible current-event backdrop. Without asserting specifics, several themes could plausibly relate:

• Policy and reimbursement — ongoing drug-pricing, PBM and Medicare/Medicaid rate debates disproportionately hit managed care and pharmacy names, consistent with the payor cluster closing near lows.
• Clinical and regulatory catalysts — the 3-5x realized-vs-implied surprises in TEM, MRNA and EBS are typical of binary data or approval-type events, where options underprice a discrete jump.
• Premium decay in speculative biotech — DBVT, CDXS, MGNX and QURE carried 100-230% implied volatility yet realized far less, a pattern often seen when event risk passes or gets pushed out.
• Rate and risk-appetite shifts — long-duration, cash-burning small caps (KPTI, STIM, CDXS) remain the most rate- and liquidity-sensitive part of the sector.